Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Phytopharm: Chinese cash burn

Article Abstract:

Phytopharm produces herbal medicines and tests plant materials on human subjects rather than isolating active ingredients. The quality and consistency of drug batches may not be easy to achieve, and regulatory approval is not certain. This means that investors in the company's share issue may be running risks. Fisons is a development partner, but Phytopharm still gives cause for concern over cash flow needs and could be too dependent on a single partner.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
Pharmaceutical Preparations, Drugs, PHYTOpharmaceuticals Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Stop taking the tablets

Article Abstract:

Powderjet Pharmaceuticals plans a 110 million pounds sterling stock flotation in May 1997. The company has developed a drug delivery system which is efficient compared to oral methods, and which is preferred by patients to injections. The system has clear benefits but there are still doubts because it is not suitable for some 90% of pharmaceuticals and has not yet gone into phase 2 trials. The stock issue represents some risk for investors.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997
Drug Delivery Systems, Powderjet Pharmaceuticals

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


GeneMedix

Article Abstract:

UK generic drugs producer GeneMedix's strategy leaves the firm vulnerable to competition and tighter patent rules, and its shares could decline further. GeneMedix makes unbranded copies of drugs, selling them to countries where the drugs are not covered by patents.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Generic Drugs, GeneMedix

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Securities
Similar abstracts:
  • Abstracts: The rise of wealth management. Covering all the bases. Avoiding the annuity trap
  • Abstracts: Dynamics of investing. A stake that's up in the air. Shrewd operators
  • Abstracts: How to discriminate. Go for the substance. Strength through harmony
  • Abstracts: The same old changes again. Good timing. Shed those shackles
  • Abstracts: Open software: can you afford it? Can you avoid it? Preparing for the real knowledge organization. Rapid skill obsolescence in an IT company: a case study of Acxiom Corp
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.